Literature DB >> 28498261

Clear Cell Carcinoma of the Uterine Cervix: A Clinical and Pathological Analysis of 47 Patients Without Intrauterine Diethylstilbestrol Exposure.

Li Yang1, Aiwen Zheng, Xiang Zhang, Xianhua Fang, Wenyong Sun, Yaqing Chen.   

Abstract

OBJECTIVES: The aim of this study was to summarize the clinical and pathological characteristics and to conduct prognosis analysis of patients who were diagnosed with clear cell carcinoma of the uterine cervix (CCCUC) and without a history of exposure to diethylstilbestrol.
METHODS: We performed a retrospective review of all the patients with CCCUC who were diagnosed and treated at Zhejiang Cancer Hospital between 1998 and 2014. Charts were reviewed for clinical and pathological characteristics, and prognosis analysis was conducted.
RESULTS: A total of 47 patients were included. Median age was 52 years. No patient had a history of exposure to diethylstilbestrol. The International Federation of Gynecology and Obstetrics stage distribution was 55.3% (n = 26) stage I, 40.4% (n = 19) stage II, 2.1% (n = 1) stage III, and 2.1% (n = 1) stage IV. Forty-two patients (89.4%) underwent radical hysterectomy and pelvic lymphadenectomy. Pathological examination revealed deep cervical stromal invasion (greater than two thirds) in 20 patients (48.4%), pelvic lymph node (PLN) metastasis in 10 patients (23.8%), lymphovascular space involvement in 9 patients (21.4%), and ovarian metastasis in 1 patient (2.4%). Advanced tumor stage (IIB-IV), larger tumor size (>4 cm), and PLN metastasis had negative effects on progression-free survival (PFS) and overall survival (OS) (P < 0.05). Adjuvant radiation therapy alone or concurrent chemoradiation therapy after radical surgery did not affect PFS or OS in patients with risk factors (P > 0.05).
CONCLUSIONS: International Federation of Gynecology and Obstetrics stage, tumor size, and PLN status were prognostic factors for both PFS and OS in patients with CCCUC. The long-term effects of adjuvant radiation therapy or concurrent chemoradiation therapy may be limited for CCCUC patients with risk factors. Future larger case series or clinical trials are required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28498261     DOI: 10.1097/IGC.0000000000000992

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol.

Authors:  Dongying Wang; Chunhua Zhao; Li Fu; Yang Liu; Weiyang Zhang; Tianmin Xu
Journal:  Obstet Gynecol Int       Date:  2019-03-26

2.  Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China.

Authors:  Ting Wang; Zhiying Lu; Xiaodan Zhang; Keqin Hua
Journal:  Int J Gen Med       Date:  2022-05-03

3.  Turn-on fluorometric immunosensor for diethylstilbestrol based on the use of air-stable polydopamine-functionalized black phosphorus and upconversion nanoparticles.

Authors:  Shuyue Ren; Ye Li; Qiyue Guo; Yuan Peng; Jialei Bai; Baoan Ning; Zhixian Gao
Journal:  Mikrochim Acta       Date:  2018-08-23       Impact factor: 5.833

4.  Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case.

Authors:  Mary G Dandulakis; Aidas J Mattis; Andrea R Hagemann; Ian S Hagemann
Journal:  Gynecol Oncol Rep       Date:  2018-01-02

5.  Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.

Authors:  Liju Zong; Qianqian Zhang; Yuncan Zhou; Yujia Kong; Shuangni Yu; Jie Chen; Youzhong Zhang; Yang Xiang
Journal:  J Immunol Res       Date:  2020-04-03       Impact factor: 4.818

6.  Clear Cell Adenocarcinoma of Uterine Cervix: A Single Institution Retrospective Experience.

Authors:  Zhimin Liu; Junyun Li; Haifeng Gu; Hua Tu; Guochen Liu; Jihong Liu
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

7.  A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure.

Authors:  Vinay Mathew Thomas; Swetha Ann Alexander; Matthew J Hadfield; James Vredenburgh
Journal:  Cureus       Date:  2020-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.